HealthRX vs Invigor Medical
Two GLP-1 desks, one scoreboard. We put HealthRX and Invigor Medical head-to-head on the published Brief Score — the same six factors, scored the same way.
Invigor Medical
The verdict
Invigor Medical takes this head-to-head.
Invigor Medical scores 88 to 86 on our six-factor Brief Score — An established telehealth pharmacy with a broad metabolic and hormone catalog and a steady price line.
That doesn't make HealthRX a bad call — it's best for readers who want an accredited, physician-supervised program with a needle-free oral tablet option on either molecule — and value a legitscript trust signal, while accepting that some tiers are company-stated. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| HealthRX | Invigor Medical | |
|---|---|---|
| Brief Score | 86/100 (B) | 88/100 (B+) |
| Semaglutide | $190/mo month-to-month ($99 first month, renews at $165) · $99/mo on a 12-month prepay ($1,188) | $199/mo |
| Tirzepatide | $239/mo month-to-month ($149 first month, renews at $214) · $179/mo on a 12-month prepay ($2,148) | $339/mo |
| Coverage | Not publicly listed | Not disclosed |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
| On the tracker | Stableprice stable | Stableprice stable |
HealthRX: Company-stated tiers held flat this cycle; the LegitScript badge and a rare oral GLP tablet are the draw, but some tiers are self-reported rather than checkout-verified.
Invigor Medical: Long-running operator; mid-market pricing unchanged this cycle.
● Not sold on either?
CoreAge Rx tops the whole ranking at 94/100.
The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.